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Abstract
Cancer stem cells (CSCs) are an uncommon subset of tumor cells capable of self-renewal, differentiating, and recreating the
parental tumor when transplanted into the murine background. Over the past two decades, efforts toward understanding CSC
biology culminated into identifying a set of signaling pathways sustaining “stemness”. Nevertheless, while metabolic
rewiring is nowadays considered a hallmark of cancer, no consensus has been reached on the metabolic features underlying
the plastic nature of CSCs, which are capable of residing in a dormant state, and able to rapidly proliferate when the need to
repopulate the tumor mass arises. An emerging concept in the field of CSC metabolism is that these cells are extremely
reliant on the activity of enzymes involved in lipid metabolism, such as stearoyl-CoA desaturase 1 (SCD1) and 3-hydroxy-3-
methylglutharyl-coenzyme A reductase (HMG-CoAR). Indeed, SCD1 and HMG-CoAR have been described as key factors
for the correct function of a number of concatenated pathways involved in CSC fate decision, such as Hippo and Wnt. In the
present review, we describe metabolic futures of CSCs with a special focus on lipid metabolism, which until now represents
an underappreciated force in maintaining CSCs and an attractive therapeutic target.
Introduction
Seminal evidence documenting that cancer cells are char-
acterized by metabolic alterations dates back to the first half
of the twentieth century, with the pioneering work of the
German physiologist Otto Warburg [1]. Central to the ori-
ginal appreciation of metabolic processes exploited by
cancer cells to cope with their increased metabolic demands
was the increased consumption of glucose in comparison to
non-proliferating normal cells. This occurs via a seemingly
paradoxical process in terms of ATP production per mole-
cule of glucose, defined as the Warburg effect or aerobic
glycolysis. Indeed, while cells generally use oxidative
phosphorylation (OXPHOS) as the main pathway to pro-
duce energy, cancer cells can produce ATP via glycolysis
even under normoxic conditions. Even though aerobic
glycolysis is significantly less efficient than OXPHOS, it is
more rapid and accounts for the glucose avidity seen in
cancer cells. Shortly after, Harry Eagle described that
optimal growth of cultured HeLa cells required an excess of
glutamine in the medium as compared to other amino acids
[2]. Moreover, glutamine was demonstrated to be the most
rapidly consumed amino acid by cancer cells, with a con-
sequent depletion of glutamine from the tumor environment
[3–6]. Glutamine consumption provides carbon and amino-
nitrogen that serve for the biosynthesis of amino acids,
nucleotides, and lipids [7]. While cancer metabolism has
traditionally been equated with the Warburg effect, a pro-
cess perceived as inefficient and considered an indirect
consequence of neoplastic transformation, the development
of more sophisticated biochemical and molecular assays
elucidated the bi-directional relationship between genetic
derangements that characterize tumors and metabolic
reprogramming. While, on the one hand, mutations in
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oncogenes and loss-of-function alterations of oncosup-
pressors increase the metabolic demands of cancer cells and
require an adaptive response to ensure cell fitness, on the
other some metabolites possess oncogenic roles, interfering
with intracellular signaling, gene expression, and cellular
differentiation [8]. On this basis, metabolic reprogramming
is nowadays listed among the so-called hallmarks of cancer
[9]. In parallel, evidence on deregulated metabolic pathway
nodes raised the idea that pharmacological inhibition of
metabolic routes may hold therapeutic implications,
prompting clinical trials that specifically looked at the
antitumor activity of compounds widely prescribed for
metabolic disorders such as diabetes and obesity (e.g.
metformin and statins) [10–20]. In this review, we describe
the origin and evolution of the CSC model. Afterwards, we
discuss recent advances in our understanding of the meta-
bolic phenotype of CSCs with special emphasis being
placed on an emerging branch of CSC metabolism, namely
lipid metabolism.
Metabolic reprogramming and the tumor
microenvironment
Metabolites produced by cancer cells not only influence
cancer cell fate, but have the potential to modify cellular
dynamics in the tumor microenvironment. It has been
widely established that a variety of non-transformed cells
such as tumor-associated fibroblasts cancer-associated
fibroblasts (CAFs), endothelial cells, and immune cells
undergo phenotypic changes when interacting with tumor
cells, in a process that further encourages tumor growth
[21]. Reprogramming of the metabolic machinery also
influences the tumor-stroma crosstalk. For instance, the
accumulation of extracellular lactate stemming from the
elevated utilization of glucose and glutamine by cancer cells
attenuates activation of dendritic and T cells, while stimu-
lating the polarization of resident macrophages to a tumor-
promoting state (M2 state or alternatively activated) [22–
25]. In such a manner, metabolic reprogramming depresses
the antitumor immune response and participates in installing
an immune-permissive microenvironment. Next, the excess
of lactate increases the production of angiocytokines by
endothelial cells, and leads to acidification of the cellular
microenvironment [26–29]. In turn, acidification of the
extracellular space stimulates the proteolytic activity of
matrix metalloproteinases and cathepsins, ultimately
enhancing matrix degradation and tumor invasion [28, 29].
Reciprocally, adverse conditions existing within the tumor
microenvironment, such as hypoxia and the paucity of
nutrients, force cancer cells to evolve metabolic strategies to
thrive in a hostile environment [30–41].
Cancer metabolism: heterogeneous by
nature
It has become increasingly clear that a unique model of
cancer metabolic program cannot transversally apply to the
entire spectrum of cancer types, nor to the various intrinsic
subtypes existing within tumors arising in a given body site.
This scenario is further complicated when considering that
tumors are heterogeneous diseases, composed by different
clones and sub-clones that harbor distinct genetic altera-
tions, replicative capabilities, and metabolic requirements
[42]. Indeed, levels of nutrient consumption, such as glu-
cose and oxygen, are spatially heterogeneous within the
same tumor mass, as routinely observed in clinical practice
with positron emission tomography-based imaging. Intra-
tumor heterogeneity was traditionally explained with Dar-
winian principles of evolution [42]. According to this view,
random acquisition of favorable mutations and epigenetic
alterations enables some clones to expand and endure per-
turbations in their microenvironment, ultimately gaining a
survival advantage over other clones. Over the past two
decades, this model was questioned by the discovery of an
uncommon cellular pool endowed with a set of unique
properties, such as the ability to self-renew and differentiate,
along with tumor-forming ability when transplanted into
immunocompromised mice [43]. Commonly defined as
cancer stem cells (CSCs), this cellular subset has gained
popularity and, with the development of specific in vitro
and in vivo assays for purification, characterization, and
quantification, CSCs have been defined as the root of
metastatic dissemination and therapeutic resistance. An
emerging concept is that CSCs rely on a variety of meta-
bolic avenues whose engagement fluctuates over time [44].
Indeed, CSCs can reside in a dormant-like state (quies-
cence), while rapidly proliferating to fulfill specific needs
(i.e. replacing dying cells after cytotoxic therapies). Intui-
tively, quiescence, self-renewal, and differentiation imply
an elevated degree of metabolic plasticity. In turn, some
typical features of tumors, such as hypoxia and low pH,
have been connected with the acquisition of stem-like traits
[45, 46].
The CSC model
First prospective identification of CSCs was provided in
1997, when a “vertical” architecture was observed in acute
myeloid leukemia resulting from the existence of a rare and
phenotypically distinct subset of tumor cells able to pro-
pagate the tumor in immune-deficient mice [47]. Ever since,
a wave of studies relying on a common experimental
approach, consisting in flow cytometry-based separation of
different cellular subsets (on the basis of the expression of
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cell-surface markers) followed by serial transplantation into
immunocompromised mice, allowed to separate a rare
fraction of tumorigenic cancer cells from the bulk of tumor
cells, which failed to recreate a neoplastic lesion when
transplanted in the murine background [48–53]. On this
basis, a hierarchical model of cancer was postulated, envi-
sioning few CSCs at the top of the pyramid that give rise to
progenitors and differentiated cells. Thus, the cardinal
property of CSCs is self-renewal, defined as the process
through which, upon cell division, a stem cell generates one
(asymmetric division) or two (symmetric division) daughter
cells that retain stem cell features, thus ensuring the main-
tenance/expansion of the stem cell compartment. Never-
theless, it is worth mentioning that non-uniform
experimental conditions have been exploited in studying
CSCs over time (i.e. freshly isolated patient-derived CSCs
vs commercial cell lines). On this basis, a great deal of
attention nowadays is posed on the experimental workflow
for CSCs isolation, purification, and characterization, with
particular emphasis on gold-standard in vivo assays. These
include serial transplantation experiments to address
tumorigenic potential and the ability to recapitulate the
histological features of the parental tumor, and limiting-
dilution assays for estimating CSC frequency.
As originally formulated, the CSC model postulated the
existence of a rigid hierarchy within a tumor. This “fixed”
state was in stark contrast with the highly dynamic clonal
evolution model, which was shaped on Darwinian princi-
ples of evolution. Nevertheless, in more recent years func-
tional studies harmonized the two models, introducing the
concept of “dynamic stemness”, a process that describes the
acquisition of stem-like traits by non-CSCs [54]. Central in
elucidating the dynamic nature of the stem cell state was the
reprogramming of fibroblasts achieved through the forced
expression of a specific set of transcription factors (Oct3/4,
Sox2, c-Myc, and Klf4) [55]. With this approach, differ-
entiated cells were reprogrammed into cells harboring the
functional properties of embryonic stem cells, defined as
induced pluripotent stem cells (iPSCs). Ever since, evidence
has accumulated conveying the message that, upon expo-
sure to opportune conditions, non-CSCs can acquire stem-
like features. This functional conversion was demonstrated
by exposing cancer cells to specific microenvironmental
conditions. More specifically, the non-stem to CSC transi-
tion was obtained upon exposure to myofibroblast-secreted
factors that activate β-catenin-dependent transcription,
through cytokines released by tumor-associated cells, via
epithelial–mesenchymal transition, and in the presence of
specific microenvironmental conditions such as hypoxia
and low pH [45, 46, 56–58]. Moreover, multiple evidence
side with the hypothesis of clonal evolution in the CSCs
pool, spanning from genetic heterogeneity of cancer-
propagating cells and the existence of distinct pools of
tumor-initiating cells to enrichment of CSCs upon exposure
to anticancer therapies or with disease progression [59–65].
Overall, the concept of “dynamic stemness” relies on evo-
lutionary principles, namely the adaption to perturbations
arising in the ecosystem. Thus, the CSC concept was refined
over the past years, and the two apparently antithetic models
nowadays appear not to be mutually exclusive.
Metabolic features of CSCs
While the metabolic portrait of CSCs has been the focus of
intense investigation in recent years, it still remains unclear
whether these cells are predominantly glycolytic or they
rather exploit OXPHOS.
The idea that CSCs are primarily glycolytic is rooted into
the supposed similarities between CSCs and their normal
counterparts. Indeed, while multipotent stem cells are gly-
colytic, their differentiated offspring mostly rely on
OXPHOS [66]. Moreover, reprogramming of normal cells
into iPSCs is accompanied by a switch from OXPHOS to a
glycolytic program, which precedes the acquisition of
pluripotency markers [67, 68]. Further supporting this view,
mitochondria in iPSCs revert to an immature state, which is
characterized by fewer and less mature mitochondria (low
content of mitochondrial DNA and low levels of intracel-
lular ATP and reactive oxygen species (ROS)) compared
with differentiated cells, whereas differentiation was cou-
pled with mitochondria maturation (functionally active
mitochondria with increased levels of ATP and ROS) [69].
In turn, the reduced levels of ROS are essential for main-
taining quiescence and self-renewal ability [70]. Regarding
studies specifically focusing on CSCs, it has been observed
that the side population exhibits higher levels of glycolytic
activity compared to the bulk of tumor cells, whereas glu-
cose starvation resulted in a decline of the side population
[71]. Consistently, glycolysis inhibition obtained by 3-
BrOP hindered tumor-forming ability [71]. The side popu-
lation assay is a flow cytometry method that exploits the
Hoechst dye efflux properties of ATP-binding cassette
(ABC) transporters, a transport system deputed to extrude
xenobiotics from the cells [72]. Thus, the side population
represents a multi-drug resistant cellular fraction enriched in
CSCs.
Likewise, basal-like breast cancer cells harboring the
CSC phenotype CD44+CD24lowEPCAM+ are dependent on
an OXPHOS to aerobic glycolysis switch [73]. A number of
studies further provided hints that CSCs are more glycolytic
than their differentiated counterparts: this was observed in
nasopharyngeal carcinoma, ovarian cancer, osteosarcoma,
glioblastoma (GBM), and colon cancer [74–78].
Lipid metabolism and cancer stem cells
Other studies reported that CSCs prevalently adopt
mitochondrial oxidative metabolism and tolerate glucose
deprivation. For instance, clonogenicity of GBM stem cells
(GBM-SCs) was abolished upon OXPHOS, but not of
glycolysis, inhibition [79]. This metabolic portrait of GBM-
SCs was linked to the activity of the oncofetal insulin-like
growth factor 2 mRNA-binding protein 2 (IMP2,
IGF2BP2), which regulates OXPHOS by participating in
the assembly and function of mitochondrial respiratory
complexes [79]. Moreover, BCL-2 inhibition efficiently
targeted OXPHOS, leading to the selective elimination of
ROSlow quiescent leukemia stem cells [80]. In pancreatic
ductal adenocarcinoma (PDAC), CD133+ CSCs rely on the
transcription factor PPARGC1A (PGC-1α), a central reg-
ulator of mitochondrial biogenesis, for proper OXPHOS
function, self-renewal, and in vivo tumor-forming capacity
[81]. Consistently, inhibition of mitochondrial respiration
triggered apoptosis in CD133+ PDAC cells. Conversely, a
MYC-mediated glycolytic program was selectively acti-
vated in more differentiated PDAC cells, a process tied to
the negative control operated by MYC on PGC-1α [81].
Studies investigating the metabolic liability of tissue-
resident stem cells provided some interesting clues that
might help dissect the metabolic portrait of CSCs, high-
lighting the importance of the tumor microenvironment in
which stem cell reside (stem cell niche). For instance,
Paneth cells, which support intestinal stem cell (ISC)
function in the intestinal crypt, exploit glycolysis to produce
lactate [82]. This, in turn, is converted into pyruvate in ISCs
to support mitochondrial OXPHOS. Likewise, OXPHOS
seems to be required for satellite cell activation and pro-
liferation [83]. Conversely, stem cells residing in hypoxic
niches (e.g. bone marrow niche), such as hematopoietic
stem cells and mesenchymal stem cells, rely on glycolysis
to fulfill their metabolic demands [84, 85]. On this ground,
it is plausible to speculate that metabolic features of CSCs
might be different in relation to the tissue of origin, as well
as in the site in which they metastasize.
Lipid metabolism and CSCs
Given the increasing interest surrounding tumor metabo-
lism, novel evidence is shedding light on alterations in lipid-
and cholesterol-associated pathways, which have often been
disregarded in the past. Proliferating tumor cells require
lipids and cholesterol, a need which is fulfilled by an
increased uptake of exogenous lipids and lipoproteins and/
or by hyper-activating the metabolic routes deputed to
produce lipids (lipogenesis) and cholesterol (mevalonate
pathway) [86]. Consistently with the belief that lipid dys-
functions are associated with more aggressive molecular
traits, a gene expression study revealed that up-regulation of
transcripts related to lipogenesis and cholesterol synthesis
pathways is associated with adverse survival outcomes in
colorectal cancer patients [87]. Moreover, lipids present in
cell membranes, and in particular cholesterol and sphingo-
lipids, form planar microdomains (lipid rafts) that, in cancer
cells, contain an array of signaling proteins and receptors
involved in pro-oncogenic and apoptotic pathways [88].
Indeed, lipid raft disruption hinders cancer cell proliferation
by inhibiting AKT activation [89]. Cancer cells also use
lipids coming from adipocytes residing in the micro-
environment as their energy source [90, 91]. The co-culture
of adipocytes and ovarian cancer cells results in the transfer
of lipids from adipocytes to ovarian cancer cells promoting
their growth, and a similar strategy is adopted by metastatic
bone marrow-derived prostate cancer cells [90, 91]. When
specifically looking at the stem cell compartment, it has
been demonstrated that both hematopoietic stem cells and
leukemia-initiating cells (LICs) rely on fatty acid oxidation
(FAO) [92, 93]. Interestingly, LICs co-opt the adipose tis-
sue niche to create a supportive microenvironment that
encourages leukemic growth and chemoresistance [93].
According to this model, LICs colonizing the adipose tissue
release pro-inflammatory cytokines that elevate lipolysis in
the gonadal adipose tissue. This, in turn, leads to the
secretion of free fatty acids that fuels FAO in LICs, via the
elevated expression of the fatty acid transporter CD36. A
similar role for CD36 was also envisioned for oral CSCs
[94]. In hepatocellular carcinoma (HCC), the nexus between
FAO and stem-like properties was mechanistically identi-
fied in the stem cell factor NANOG, which represses
OXPHOS genes and activates FAO [95]. This effect might
be connected to the uncoupling of FAO from ATP synth-
esis, as observed in leukemia cells that exploit de novo fatty
acid synthesis to support FAO [96].
Next, the excess of lipids in cancer cells is stored into
cytoplasmic organelles, probably originating from the
endoplasmic reticulum and/or the Golgi apparatus, called
lipid droplets (LDs) [86]. Elevated levels of LDs are asso-
ciated with tumor aggressiveness and accumulation of LDs
has been observed in circulating tumor cells whose enu-
meration, in turn, has been proposed for predicting survival
outcomes [97–99]. An increased content of LDs is a dis-
tinctive feature of CD133+ colorectal CSCs (CR-CSCs), as
revealed by Raman spectroscopy imaging [100]. Indeed, a
direct correlation was observed between LD content,
CD133 expression, and activated Wnt signaling in CR-
CSCs. Moreover, upon sorting CR-CSC lines in LDsHigh
and LDsLow, it was observed that LDsHigh cells had greater
clonogenic potential, as assessed by in vitro sphere-forming
efficiency and in vivo tumor-forming ability.
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Lipid metabolism and CSCs: the role of SCD1
The connection between lipid metabolism and CSC fate
mostly stemmed from studies exploring the activity of
stearoyl-CoA desaturase 1 (SCD1) (Fig. 1) [101–104].
SCD1 is a central enzymatic node in the conversion of
saturated fatty acids into monounsaturated fatty acids
(MUFAs) [105]. MUFAs represent the precursors of a
number of lipids essential for plasma membranes, such as
triglycerides, cholesterol esters, diacylglycerols, and wax
esters [105].
Gene expression profiling carried out to identify genes
differentially expressed between pleural effusion-derived
lung cancer cells growing as spheroids or under adherent
conditions revealed a significant up-regulation of SCD1 in
tumor-spheres [101, 106, 107]. SCD1 inhibition, achieved
either by RNA interference or the small-molecule inhibitor
MF-438, hindered sphere-forming efficiency in a process
accompanied by the reduced expression of stem cell mar-
kers including ALDH1A1, Nanog, and Oct4. Spheroids
treated with the SCD1 inhibitor MF-438 showed many
ultrastructural features of cellular damage, such as cyto-
plasmic vacuolization, mitochondrial swelling, apoptotic
nuclei and, in some instances, nuclear fragmentation.
Moreover, pharmacological inhibition of SCD1 induced
anoikis in ALDH1A1-positive cells, and spheroids gener-
ated in the presence of MF-438 had decreased tumorigenic
potential upon xenotransplantation in mice as compared to
untreated cells. Of note, more differentiated lung cancer
cells were unaffected by the abrogation of SCD1 function,
thus suggesting that SCD1 activity and the consequent
dependence on MUFA generation may be a distinctive trait
of CSCs. Moreover, SCD1 inhibition reverted chemoresis-
tance in lung CSCs [108]. These findings are consistent
with a high-throughput screen of small molecules carried
out to identify compounds capable of killing human plur-
ipotent stem cells, revealing that an SCD1 inhibitor was the
most potent compound in inducing endoplasmic reticulum
(ER) stress response, attenuation of protein synthesis, and
cell death [109]. Mechanistically, SCD1-mediated regula-
tion of CSCs was linked to the control operated by this
enzyme on two closely related oncoproteins, namely the
Hippo transducers Yes-associated protein (YAP) and its
paralogue transcriptional co-activator with PDZ-binding
motif (TAZ) [102]. YAP/TAZ represent the transcriptional
module of the Hippo signaling, an evolutionary conserved
pathway that plays a central role during organ development
and tissue repair after injuries [110]. Over the past years,
deregulated Hippo pathway and aberrant YAP/TAZ-driven
transcription have been observed in multiple tumor types,
and tied to the generation of CSCs [110]. By silencing
SCD1 in lung cancer spheroid cultures, Noto et al. [102]
documented a significant decrease of YAP/TAZ at the
protein level together with a decline in their nuclear
expression. Furthermore, SCD1 inhibition hampered YAP/
TAZ-driven gene transcription, as documented by reduced
mRNA levels of the YAP/TAZ target genes birc5 and ctgf.
Intriguingly, both SCD1 and YAP/TAZ are molecularly
Fig. 1 SCD1-mediated control
of CSCs. SCD1 enhances the
production of lipid-modified
Wnt proteins that activate the
canonical Wnt pathway.
Activation of the Wnt pathway
leads to the release of both β-
catenin and YAP/TAZ from the
destruction complex. This
enables β-catenin and YAP/TAZ
to translocate to the nucleus
where, upon interaction with
their transcriptional partners,
they mediate the reprogramming
of cancer cells into CSCs. SCD1
promotes stemness also via the
activation of the NF-kB pathway
that, in turn, feeds a positive
feedback loop by increasing the
expression levels of lipid
desaturases
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intertwined with the wnt/β-catenin pathway [111, 112].
Consistently, SCD1 abrogation also led to a preferential
cytoplasmic distribution of β-catenin along with a reduction
in axin2 levels, a transcriptional target of the β-catenin-
TCF/LEF complex [102]. The model proposed for
explaining the dual control operated by SCD1 on YAP/TAZ
and β-catenin envisioned that SCD1 mediates the release of
Wnt ligands. This results in the activation of the canonical
Wnt signaling, with the consequent dislocation of β-catenin
and YAP/TAZ from the β-catenin destruction complex,
their nuclear accumulation and transcription of target genes.
As already reported in a study exploring the effects of Wnt
signaling and YAP/TAZ on the expansion of intestinal
progenitor cells [111], the crosstalk between YAP/TAZ and
Wnt occurred independently from the activation of the
Hippo regulatory module, the negative controller of YAP/
TAZ. In line with the oncogenic role of SCD1, YAP/TAZ,
and β-catenin, the combined expression of SCD1/YAP,
SCD1/TAZ, and SCD1/β-catenin were associated with
inferior survival outcomes [102]. Evidence from breast
CSCs (BCSCs) enforced the link between SCD1, the Wnt
pathway, and stemness [103]. El Helou et al. [103] carried
out a miRNome-wide loss- and gain-of-function screens
that led to the identification of micro-RNA (miR)-
600 silencing as one of the most potent hits in expanding
the BCSC pool. MiR-600-mediated control of BCSCs was
correlated with the targeting of SCD1. Indeed, the knock-
down of miR-600 de-repressed SCD1 that, in turn, gener-
ated oleic acid that is essential for the secretion of lipid-
modified Wnt proteins that activate the canonical Wnt
pathway. At the molecular level, miR-600 inhibition
increased b-catenin transactivator activity, promoted its
nuclear accumulation, and increased Wnt3a levels in the
medium [103]. Next, Li et al. [104] recently reported that
ovarian CSCs (O-CSCs) had significantly higher levels of
unsaturated lipids compared with their more differentiated
counterparts. Consistently, SCD1 mRNA expression level
was significantly higher in ALDH+/CD133+ cells as
compared with ovarian cancer cells that did not harbor this
repertoire of cell-surface markers. Inhibition of SCD1
obtained with small-molecule inhibitors (CAY10566 and
SC-26196) or shRNAs reduced lipid unsaturation levels in
spheroids, and led to a drop in the expression of a battery of
stem cell markers (ALDH1A1, Sox2, Nanog, and Oct-4).
Not surprisingly, SCD1 inhibition hampered sphere-
forming efficiency in vitro and suppressed tumor-forming
ability. Remarkably, ovarian cancer cells grown as mono-
layers (containing fewer CSCs) and non-transformed cells
(human dermal fibroblasts) were fairly insensitive to desa-
turase inhibitors, thus further supporting the idea that lipid
desaturation represents a distinctive feature of CSC and a
potential CSC-directed therapy. Mechanistically, pharma-
cological inhibitors of SCD1 downregulated a set of stem
cell-related signalings in OC spheroids including nuclear
factor-kB (NF-kB), Hedgehog, and Notch. In particular,
desaturase inhibition suppressed NF-kB transcriptional
activity, as denoted by the reduced expression of IL-6 and
IL-8. In turn, forced overexpression of p65 significantly up-
regulated SCD1, whereas the NF-kB inhibitor DMAPT
decreased both lipid unsaturation and SCD1 levels in
tumor-spheres [104]. Collectively, these data indicated the
existence of a positive feedback loop between SCD1 and
NF-kB signaling that sustains “stemness” in ovarian cancer
cells. Similarly, the silencing of ferritin heavy chain in
ovarian cancer cells increased the expression of both SCD1
and stem cell markers, in a process accompanied by
epithelial-to-mesenchymal transition and increased sphere-
forming efficiency [113]. Recently, it has been observed
that SCD1 regulates liver CSCs (HCC), whereas its inhi-
bition forced these cells to differentiate via the ER stress-
induced unfolded protein response (UPR) [114]. Thus, the
anti-CSC properties of SCD1 inhibition seems to be cor-
related with both the inhibition of specific signaling path-
ways linked to “stemness” and a broader effect represented
by ER stress/UPR activation. Finally, the connection
between SCD1 and signaling transduction pathways
extends beyond stem cell-associated molecular networks.
For instance, Zhang et al. [115] provided evidence that
EGFR phosphorylates SCD1, thus maintaining SCD1 pro-
tein stability and increasing MUFA levels in a process that
feeds lung cancer growth.
Overall, enhanced activation of SCD1 and the con-
sequent production of MUFAs appear to be a hallmark of
CSCs. On this ground, pharmacological inhibition of SCD1
function may delineate a metabolic vulnerability of CSCs.
Lipid metabolism and CSCs: the role of HMG-
CoAR
3-Hydroxy-3-methylglutharyl-coenzyme A reductase
(HMG-CoAR) is the rate-limiting enzyme in the mevalo-
nate pathway and the molecular target of statins, the popular
cholesterol-lowering agents [116]. The mevalonate pathway
represents the metabolic route that leads to the production of
steroid-based hormones, cholesterol, and non-sterol iso-
prenoids. Moreover, this metabolic avenue profoundly
affects intracellular signal transduction. Indeed, farnesyl
pyrophosphate (FPP) and geranylgeranyl pyrophosphate
(GGPP), produced in the mevalonate cascade, are required
for protein prenylation, a post-translational modification
process that enables correct membrane tethering of Ras and
Rho family of small guanosine triphosphatases (GTPases).
In turn, small GTPases are essential for the function of G-
protein-coupled receptors (GPCRs) that, in a neoplastic
background, mediate an array of tumor-enhancing functions
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ranging from proliferation and survival to invasion and
metastasis [116].
A gene expression profile carried out for identifying
molecular networks selectively activated in BCSCs revealed
that enzymes of the mevalonate pathway were over-
represented in basal-like tumor-spheres as compared to
matched cells growing under adherent conditions [117].
Inhibition of the mevalonate cascade through simvastatin
reduced the CSC population, as assessed by ALDEFLUOR
assay, and decreased sphere-forming efficiency. Con-
versely, addition of mevalonate to the culture medium res-
cued the ALDEFLUOR-positive population and sphere-
forming ability. Mevalonate pathway-mediated main-
tenance of the BCSC compartment was found to be
dependent on protein geranylgeranylation. Indeed, the ger-
anylgeranyl transferase inhibitor GGTI-298 reduced the
CSC population by hindering correct membrane anchoring
of RHOA. Molecularly, defective activity of RHOA
enabled P27kip1 to translocate to the nucleus, where it
inhibits RB activation ultimately favoring CSC differentia-
tion [117]. Likewise, Sorrentino et al. [118] demonstrated
that the mevalonate pathway promotes nuclear localization
and activity of YAP/TAZ, whereas the administration of
statins led to an accumulation of YAP/TAZ in the cyto-
plasm. The block imposed by statins on the YAP/TAZ
transcriptional program impaired self-renewal ability of
BCSCs, as monitored by mammosphere-forming assay, and
these effects were recapitulated with other compounds act-
ing at different levels of the mevalonate cascade, including
the farnesyl diphosphate synthase inhibitor zoledronic acid
and the geranylgeranyl transferase inhibitor GGTI-298.
Metabolic control of YAP/TAZ was linked to the produc-
tion of GGPP with the consequent activation of RHOA, and
occurred in a LATS1/2-independent manner. These findings
were further corroborated by experiments in Drosophila, an
established model system for studying the effects of Hippo
pathway component manipulation. Indeed, while the forced
expression of the YAP/TAZ orthologue Yorkie caused a
well-known phenotype characterized by a dramatic over-
growth or various organs and appendages, statins or the
silencing of the endogenous geranylgeranyl transferase
(ggt-I) rescued tissue overgrowth and inhibited the Yorkie
target genes Diap-1 and expanded (Fig. 2) [118].
Next, it has been recently observed that brain tumor-
initiating cells (BTICs) are characterized by elevated
mRNA expression levels of mevalonate pathway genes,
even including HMG-CoAR, as compared to their differ-
entiated counterparts [119]. Inhibition of HMG-CoAR by
shRNAs or statins consistently reduced sphere-forming
efficiency. Overexpression of mevalonate pathway genes
was linked to MYC-induced gene transcription and, in turn,
the mevalonate pathway regulates MYC, thus indicating the
existence of a feed-forward regulatory loop between the
mevalonate cascade and MYC that sustains BTICs.
Finally, it is interesting to note that both HMG-CoAR
and SCD1 have been associated with CSC fate through the
activation of oncogenic YAP/TAZ, albeit via different
molecular mechanisms. Indeed, the mevalonate cascade
promotes YAP/TAZ-driven gene transcription via protein
prenylation and Rho GTPases that, in turn, activate YAP/
TAZ [118]. Conversely, the connection between SCD1 and
CSCs relies on functional and biochemical evidence that
Fig. 2 HMG-CoAR-mediated
control of CSCs. The
mevalonate cascade culminates
in the production of FPP and
GGPP, which are essential for
correct membrane anchoring of
RHO GTPases. In turn, RHO
GTPases maintain “stemness” by
activating the Hippo transducers
YAP/TAZ and by promoting the
degradation of P27kip1
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collocate YAP/TAZ in the β-catenin destruction complex
[111]. This latter encompasses a set of proteins that, in the
absence of Wnt ligand stimulation, retains β-catenin in the
cytoplasm and enables its degradation. SCD1 promotes the
secretion of lipid-modified Wnt proteins that activate the
canonical Wnt pathway, thus disrupting the β-catenin
destruction complex and ultimately leading to the nuclear
accumulation of both YAP/TAZ and β-catenin [103].
Therapeutic targeting of SCD1 and HMG-
CoAR: challenges and opportunities
Evidence converge on assigning a CSC-promoting function
to the excess of MUFAs generated by SCD1. In this regard,
two aspects deserve particular mention. First, elevated
SCD1 activity seems to be a hallmark of CSCs, given that
both non-CSCs and non-transformed cells survived unaf-
fected SCD1 inhibition [101, 104]. This holds promise from
a therapeutic perspective, given that SCD1 inhibition might
selectively target CSCs, while sparing normal cells, thus
minimizing side effects. Second, SCD1 lies at the center-
piece of an intricate molecular network that co-regulates
various signaling pathways widely associated with CSC
fate, such as Hippo, Wnt, and NF-kB [102–104]. Thus,
pharmacological inhibition of SCD1 may hold the potential
to shut down multiple crosstalking oncogenic routes con-
trolling CSC functions, which are currently undruggable
with specific inhibitors. Nevertheless, it is worth mentioning
that the forces driving SCD1 transcriptional and post-
transcriptional up-regulation still remain largely unknown.
Clarifying the molecular network accountable for the
increased SCD1 transcription and enzymatic activity seen in
CSCs is a node that should be unraveled to fully appreciate
the therapeutic potential of SCD1-directed therapy. Indeed,
the existence of positive feedback loops controlling SCD1
expression may represent an adaptive mechanism CSCs
evolve in order to adapt to pharmacological inhibition of
SCD1.
Similar considerations apply to the mevalonate pathway,
with the advantage that enzymes of the mevalonate cascade
can be inhibited with compounds already in use in clinical
practice, such as statins and nitrogen-containing bispho-
sphonates. Even though the pharmacological targeting of
protein prenylation has not yet yielded convincing proof of
efficacy [120], some strategies might provide further evi-
dence encouraging their clinical development. First, pre-
surgical window-of-opportunity trials, consisting in the
short-term administration of a given compound in the time
elapsing between diagnosis and surgery, can provide evi-
dence on whether these agents are actually able to target the
CSC compartment [10]. Indeed, availability of pre- and
post-treatment tissues offers the possibility to evaluate
CSC-related endpoints, spanning from the evaluation of
CSC markers and/or CSC gene modules to modification in
sphere-forming efficiency. Second, it is unlikely that the
administration of mevalonate pathway-targeting agents in
the metastatic setting results in a significant improvement of
survival outcomes, given that this approach does not con-
figure the targeting of an oncogene addiction capable of
producing a rapid tumor shrinkage. Conversely, the delivery
of statins or farnesyltransferase inhibitors in conditions
characterized by a low tumor burden (adjuvant setting)
might efficiently kill residual/disseminated CSCs.
Conclusions
Over the past years, there has been compelling evidence
supporting the view that CSCs account for the maintenance
of neoplastic lesions, distant dissemination, and resistance
to anticancer therapies. Functional characterization of sig-
naling pathways required for self-renewal was recently
paralleled by studies that delineated the central role of
metabolic reprogramming in the control of CSC fate.
As anticipated, whether CSCs actually utilize glycolysis
or OXPHOS is still a matter of debate, even though the
preferential use of OXPHOS may generate a selective
advantage in an environment characterized by limited
resources. Nevertheless, it is worth noting that a series of
hurdles are encountered when attempting to decipher the
metabolic portrait of CSCs. First, CSCs are intrinsically
plastic and the stem cell state is a dynamic condition. Thus,
metabolically plasticity may characterize CSCs, as they can
either reside in a quiescent state or proliferate to replenish
the original tumor mass. For instance, it has been proposed
that, when quiescent, CSCs harbor an oxidative phenotype;
in contrast they switch to a combined glycolytic/oxidative
metabolic program when forced to proliferate [44]. Second,
poor adherence to gold-standard assays for CSC isolation
and quantification (long-term clonal growth in functional
repopulation experiments and limiting-dilution transplanta-
tion assays) generated confusion in the CSC field. This
aspect is further remarked when interpreting studies on CSC
metabolism, where different experimental conditions have
been used, with some reports exploiting commercial cell
lines and others freshly isolated, patient-derived CSCs.
Third, CSC frequency seems to be higher than hypothesized
in the past, as it is highlighted with the use of extremely
immunocompromised mice (NOD/SCID vs NOD/SCID
interleukin-2 receptor gamma chain null mice) [59]. Fourth,
current animal models lack adequate stromal support, thus
resulting in the deprivation of paracrine-acting signals
involved in “stemness” acquisition. In addition, this leads to
underestimating the effects of metabolites released by can-
cer cells on the various cell types cohabiting the
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microenvironment. As aforementioned, lactate affects the
function of various non-transformed cell types, even
including immune cells, thus participating in installing a
pervasive relationship between cancer cells and their
neighbor non-transformed cells. Collectively, these obser-
vations call for extreme caution when interpreting studies
describing metabolic alterations of CSCs, and highlight
non-negligible, and still unresolved, issues that need to be
addressed to fully appreciate the metabolic repertoire of
CSCs. In our opinion, the following points need to be
clarified: (i) the link between metabolic plasticity and the
transition among the various states characterizing CSCs
(quiescence, self-renewal, differentiation), (ii) the way
through which CSC metabolism is influenced by micro-
environmental conditions and vice versa, and (iii) the elu-
cidation of metabolic changes plausibly occurring at the
CSC levels upon administration of anticancer therapies,
based on the documented CSC enrichment occurring after
conventional anticancer therapies [61, 121].
To sum up, metabolism is no longer viewed as a mere
epiphenomenon that accompanies malignant transformation
and the transition between the various states that denote the
intrinsic plasticity of CSCs. Rather, metabolic plasticity
appears to be a central force that enables CSCs to modify
their replicative capabilities according to specific needs.
Given the considerable interest driven by the development
of CSC-directed therapies, dissecting the metabolic features
of CSCs may represent a novel therapeutic strategy to
achieve the goal of CSC elimination. To this end, adherence
to gold-standard assays for CSC characterization along with
the use of humanized mouse models able to re-create the
supportive infrastructure of human tumors appears neces-
sary steps towards achieving a full appreciation of the
metabolic vulnerability of CSCs and its clinical
exploitability.
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